arrow
H

Hagai Tavori

Sanofi
H指数:28
被引数:2,459

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Lipoprotein(a), smoking, and diabetes are additive but not interactive risk factors for major adverse cardiovascular events after acute coronary syndrome

脂蛋白(a)、吸烟和糖尿病是急性冠脉综合征后主要不良心血管事件的相加但非交互风险因素

2026-08-310
OAAI
Efficacy and safety of alirocumab once-monthly in patients with atherosclerotic cardiovascular disease and without history of an acute atherothrombotic event

阿利罗鲁单抗每月一次在无急性动脉粥样硬化性血栓事件病史的动脉粥样硬化性心血管疾病患者中的有效性和安全性

2026-07-180
OAAI
Small, dense LDL-C as a predictor of cardiovascular risk and benefit of alirocumab in patients with recent acute coronary syndrome receiving optimized statin treatment

小而密低密度脂蛋白胆固醇作为心血管风险的预测因子以及阿利罗库玛单抗在近期急性冠状动脉综合征患者中接受优化他汀类药物治疗后的获益

2026-04-170
OAAI
Efficacy and safety of alirocumab in patients with established atherosclerotic vascular disease before the first cardiovascular event: Pooled analysis of Phase 3 ODYSSEY studies

阿利罗鲁单抗在首次心血管事件发生前,对于已确诊动脉粥样硬化性血管疾病患者的疗效与安全性:ODYSSEY III期研究的合并分析

2025-10-220
OAAI
Divergent low-density lipoprotein receptor (LDLR) linked to low VSV G-dependent viral infectivity and unique serum lipid profile in zebra finches

与斑马雀的低VSV G依赖性病毒感染性和独特的血清脂质谱相关的不同的低密度脂蛋白受体 (LDLR)

2021-04-266
OAAI
Pharmacological targeting of coagulation factor XI mitigates the development of experimental atherosclerosis in low-density lipoprotein receptor-deficient mice
2021-04-0136
OAAI
Role of PAI-1 in hepatic steatosis and dyslipidemia
2021-01-1147
OAAI